Evaluation of the Effect of Rosuvastatin on Portal Hypertension and Variceal Bleeding in Children with Compensated Cirrhosis

سال انتشار: 1404
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 185

فایل این مقاله در 11 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_INJPM-13-1_003

تاریخ نمایه سازی: 26 اسفند 1403

چکیده مقاله:

Background: Portal hypertension, a complication of chronic liver disease in children, can lead to severe gastrointestinal bleeding and an increased need for hospitalization and endoscopic treatment, potentially resulting in death. Statins, known for their anti-inflammatory, antioxidant, and anti-fibrotic effects, are used in the treatment of many chronic diseases. This study aimed to investigate the effects of rosuvastatin on improving portal pressure and esophageal varices while reducing bleeding associated with these conditions in children with cirrhosis.Methods: This randomized clinical trial was conducted in children with compensated liver cirrhosis at Akbar Children's Hospital in Mashhad, Iran, between March ۲۰۲۳ and November ۲۰۲۴. Initially, endoscopy and Doppler ultrasound were performed on ۳۲ patients aged ۷–۱۷ years. The control group received standard treatments for portal hypertension, while the intervention group received rosuvastatin tablets in addition to standard treatments. After a ۶-month period, Doppler ultrasound and control endoscopy were repeated. All clinical, laboratory, sonographic, and endoscopic data were analyzed by a statistician, and the results were reported.Results: The study included ۳۲ children with cirrhosis (۱۶ in the control group and ۱۶ in the intervention group). The number of cases showing a decrease in ultrasonographic parameters of portal hypertension (SA-RI and RRA-RI) was higher in the rosuvastatin group (p=۰.۱۴ and ۰.۳۷). The grades of esophageal varices decreased by ۲۶.۷% and ۲۰% in the control and rosuvastatin groups, respectively (p=۰.۶۶). Esophageal variceal bleeding occurred in ۱۳.۳% of cases in the control group and in ۲۵% of cases in the rosuvastatin group,with no statistically significant difference between the two groups (p=۰.۴۱).Conclusion: Over the ۶-month follow-up period, rosuvastatin did not demonstrate a beneficial effect in reducing portal hypertension and variceal bleeding in children with compensated liver cirrhosis.

نویسندگان

Maryam Marefat

Fellowship, Department of Pediatrics, Facility of Medicine, Mashhad University of Medical Science, Mashhad, Iran.

Mohammad Ali Kiani

Professor, Department of Pediatrics, Facility of Medicine, Mashhad University of Medical Science, Mashhad, Iran.

Masoud Mahdavirashed

Associate Professor, Department of Radiology, Facility of Medicine, Mashhad University of Medical Science, Mashhad, Iran.

Monavar Afzalagaie

Assistant Professor , Department of Biological Statistics, Facility of Hygiene, Mashhad University of Medical Science, Mashhad, Iran.

Saeed Mohammadi

Fellowship, Department of Pediatrics, Facility of Medicine, Mashhad University of Medical Science, Mashhad, Iran.

Hamidreza Kianifar

Professor, Department of Pediatrics, Facility of Medicine, Mashhad University of Medical Science, Mashhad, Iran.

Seyyed Ali Jafari

Professor, Department of Pediatrics, Facility of Medicine, Mashhad University of Medical Science, Mashhad, Iran.

Maryam Khalesi

Associate Professor , Department of Pediatrics, Facility of Medicine, Mashhad University of Medical Science, Mashhad, Iran.

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Zhang C, Liu Y, Zhao H, Wang G. Global, regional, ...
  • Ma D, Liu X, Ai G, Pan W, Liu L, ...
  • Peng L, Wu S, Zhou N, Zhu S, Liu Q, ...
  • Eldredge JA, Hardikar W. Current status and future directions of ...
  • Sahota AK, Shapiro WL, Newton KP, Kim ST, Chung J, ...
  • Norsa L, Nicastro E, Di Giorgio A, Lacaille F, D’Antiga ...
  • Aftab K, Khurshid A, Fayyaz A, Jabeen I. Causes of ...
  • Sooraj K, Shivani FN, Khan MH, Kumar RR, Bai S, ...
  • Nishino K, Kawanaka M, Manabe N, Suehiro M, Kawamoto H, ...
  • Gratacós-Ginès J, Pose E. Review of the role of statins ...
  • Sharpton SR, Loomba R. Emerging role of statin therapy in ...
  • Moctezuma-Velazquez C, Abraldes JG. The role of statins in cirrhosis. ...
  • Sung S, Al-Karaghouli M, Kalainy S, Cabrera Garcia L, Abraldes ...
  • Kreidieh M, Hamadi R, Alsheikh M, Al Moussawi H, Deeb ...
  • Trebicka J. Statins in Compensated and Decompensated Cirrhosis: Approaching the ...
  • Agarwal R, Wisnu W. The effect of statin therapy on ...
  • De Gaetano V, Pallozzi M, Cerrito L, Santopaolo F, Stella ...
  • Guixé-Muntet S, Quesada-Vázquez S, Gracia-Sancho J. Pathophysiology and therapeutic options ...
  • Sheng JY, Meng ZF, Li Q, Yang YS. Recent advances ...
  • Rodrigues SG, Mendoza YP, Bosch J. Investigational drugs in early ...
  • Vijayaraghavan R, Jindal A, Arora V, Choudhary A, Kumar G, ...
  • Wani ZA, Mir MM, Lone SN, Khan AA, Rather MK. ...
  • Bishnu S, Ahammed SM, Sarkar A, Hembram J, Chatterjee S, ...
  • Pollo-Flores P, Soldan M, Santos UC, Kunz DG, Mattos DE, ...
  • Alsaeid M, Sung S, Bai W, Tam M, Wong YJ, ...
  • Wan S, Huang C, Zhu X. Systematic review with a ...
  • Pfisterer N, Schwarz M, Schwarz C, Putre F, Ritt L, ...
  • Werida R, Khairat I, Khedr NF. Effect of atorvastatin versus ...
  • نمایش کامل مراجع